- Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). BE j Cancer 84\(Suppl. 1), 3–10 (2001).
- Demetri GD. Anemia and its functional consequences in cancer patients: current challenges im. management and prospects for improving therapy. BE j Cancer 84, (Suppl. 1), 31–37 (2001).
- ••A brief, but clear and comprehensivepresentation of the problems engendered by anemia in cancer patients and of the current and possible future treatment options.
- Moliterno AR, Spivak JL. Anemia in cancer. Hematol Oncol Clin. North Am.10,346–363 (1995).
- DeVita VT, Hellmann S, Rosenberg SA. Cancer: Principles and practice of oncology 4th Edition, Lippincott, Philadelphia, USA (1993).
- Agency for Healthcare Research and Quality. Uses of epoetin for anemia in oncology. Evidence Report/Technology Assessment No. 30, AHRQ Publication Number 01-E008, Rockville, USA (2001).
- Bottomley A. Measuring quality of life in the anemic cancer patient. In: Anemia in cancer Bokemeyer C, Ludwig H. (Eds). ESO Scientific Updates vol. 6, Elsevier, Oxford, UK. 55–66 (2001).
- Goodnough LT, Brecher ME, Kanter MET et al Transfusion medicine. First of two parts - Blood transfusions. N Engl. I Med340,438–447 (1999).
- Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood97,1180–1195 (2001).
- Seidenfeld J, Piper M, Flamm C etal Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. j Natl. Cancer Ins 93,1204-1214 (2001).A careful and methodically well-founded systematic review and meta-analysis of the use of epoetin against anemia in cancer patients.
- Beguin Y. Prediction of response to rHuEPO. In: Anemia in cancer Bokemeyer C, Ludwig H. (Eds). ESO Scientific Updates vol. 6, Elsevier, Oxford, 153–166 (2001).
- Sheffield R, Sullivan SD, Saltiel E,Nishimura L. Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia. Ann. Pharmacother 31, 15–22 (1997).
- Littlewood T The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin. Oncol 28\(Suppl. 8), 49–53 (2001).
- Neymark N. Pharmacoeconomic analyses of the use of rHuEPO in chemotherapy-induced anemia of cancer patients. In: Anemia in cancer Bokemeyer C, Ludwig H. (Eds). ESO Scientific Updates vol. 6, Elsevier, Oxford, UK. 189–205 (2001).
- Barosi G, Liberato NL. The cost- effectiveness of rhEPO use in anemia of cancer. In: rliBythropoetin in Cancer Supportive Treatment, Smith JF, Boogaerts MA, Ehmer BRM (Eds.) Marcel Dekker, New York, USA (1996).
- Barosi G, Marchetti M, Liberato NL. Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia. BE Cancer78, 781–787 (1998).
- Drummond ME, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BE Med. 1. 313, 275–283 (1996).
- Meadowcroft AM, Gilbert CJ, Maravich-May D, Hayward SL. Costs of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy. Am. j Health Syst. 55,1898–1902 (1998).
- Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB. Cost-effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia. PharmacoEconomics 16,459–472 (1999).
- Abels RI, Larhot KM, Krantz KD, BryantEC. Recombinant human erythropoetin (r-huEPO) for the treatment of anemia incancer. In: Blood cell growth factors: their present, and future use in hematology and oncology Proceedings of the Beying Symposium. Murphy MJ (Ed.) Alpha Med. Press, Ohio, USA 121–141 (1991).
- Ortega A, Dranitsaris G, Puodziunas ALV. What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis. Cancer 83,2588–2596 (1998).
- •Cost-benefit analysis using state-of-the-art methods for elicitation of willingness-to-pay and determining net benefits of the use of epoetin in cancer patients with severe anemia.
- Cremieux PY, Barrett B, Anderson K etal Cost of out-patient blood transfusion in cancer patients. j Clin. Oncol 18,2755–2761 (2000).
- Barosi G, Marchetti M. The clinical utility of epoetin in cancer patients: a matter of perspective. I-Lematologica 85,449–450 (2000).
- Cleeland CS, Demetri GD, Glaspy J etal Identifying hemoglobin level for optimal quality of life: an incremental analysis. ASCO Proceedings 18(574a), 2215 (1999).
- Bottomley A, Thomas R, van Steen K etal.Human recombinant erythropoietin and quality of life: A wonder drug or something to wonder about? Lancet Oncology (In Press).
- Littlewood TJ, Bajetta E, Nortier JWR etal Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. Clin. Oncol 19,2865–2874 (2001).
- Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systematic, quantitative review. Cancer 91, 2214–2221 (2001).
- Höckel M, Vaupel P Biological consequences of tumor hypoxia. Semin. Oncol 28\(Suppl. 8), 36–41 (2001).
- Höckel M, Vaupel P Tumor hypoxia: definitions and current clinical, biologic and molecular aspects. j Natl. Can. Ins. 93, 266–276 (2001).
- Goodnough LT, Skikne B, Brugnara C. Erythropoietin, iron and erythropoiesis. B/ooc/96,823–833 (2000).
Expert Review of Pharmacoeconomics & Outcomes Research
Volume 1, 2001 - Issue 2